Two papers: vaccines plus niche competitors clear gut pathogens, and aged B cells drive T-cell aging.
It combines two components: an oral whole-cell inactivated vaccine that induces strong IgA against the pathogen, and a live non-pathogenic competitor bacterium occupying the same metabolic niche, digesting the same sugars, so it out-competes the pathogen while IgA simultaneously targets and clears the harmful strain.
Answered around 10:14Vaccination alone or the competitor alone only reduced wild-type Salmonella modestly. Combining both gave near-complete clearance, preventing systemic spread and eliminating intestinal inflammation. Clearance was equally effective whether the non-virulent competitor Salmonella was introduced days or weeks before the infection, so the timing was not critical.
Answered around 12:58They altered their modified competitor's ability to metabolize a sugar that wild-type Salmonella also needs, and even that small loss made the protective effect disappear. You really do need overlap in the competitor's ability to take over the metabolism of the wild-type bug for the strategy to work.
Answered around 13:38Yes. A commensal E. coli strain, 8178, with partial metabolic overlap with Salmonella reduced the initial Salmonella expansion and prevented gut inflammation when combined with vaccination, even though it induced no immune response itself. Partial overlap was enough, so an engineered competitor was not required.
Answered around 17:39They colonized mice persistently with a different commensal E. coli without antibiotics, then gave an oral vaccine against that bug plus a cocktail of competing non-targeted E. coli strains. The combination completely eliminated the target strain in 50% of the mice and strongly suppressed it in the rest.
Answered around 19:28Aged B-cell deficient muMT mice differed greatly from aged wild-type mice: far more naive T cells and fewer exhausted, memory, inflammatory ones, measured in the spleen by single-cell RNA sequencing. Their T cells looked young, while the wild-type aged mice showed the aged phenotype.
Answered around 35:39Yes. They had slightly lower body weight, a much better 31-index frailty score, better glucose tolerance, less fibrosis, improved grip strength, and differences in senescence-related genes in the liver and lungs. They also lived longer: the wild-type mice died quicker than the B-cell deficient ones.
Answered around 45:20They depleted B cells in 14-to-15-month-old middle-aged mice with an anti-CD20 monoclonal antibody once every two weeks for twelve weeks, then stopped. Those mice showed the improved T cells and the improved frailty, so the benefit did not require growing up without B cells.
Answered around 51:27They first analyzed publicly available data and found old B cells had far more going on in insulin-signaling genes than young ones. Using Cre-lox, they knocked out the insulin receptor only in B cells, leaving the mouse metabolically normal, and those B cells never acquired the problem phenotype.
Answered around 1:00:14No, they caution against it. These mice live in SPF conditions: sterile water and food, HEPA-purified air, daily checks, sentinel mice, so they never meet the colds people catch every year. Without B cells in ordinary life it would not be great, so this is no long-term solution.
Answered around 46:41“It would be an antibiotic free way to change the microbiome in a way that prevents infection.”
“And they saw that the T cells in the old B cell deficient mice resembled the T cells from the young wild type mice.”
“So the wild-type mice die quicker than the B-cell deficient mice.”
“They had fresh water, and they still died at 30.”
“Vaccine-Enhanced Bacterial Replacement & B Cell Aging.” https://traffic.libsyn.com/secure/immune/Immune102.mp3. Transcript summary by WhipScribe, https://whipscribe.com/transcript-pages/vaccine-enhanced-bacterial-replacement-b-cell-aging.html.